...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Nephron-sparing surgery for de novo renal cell carcinoma in allograft kidneys.
【24h】

Nephron-sparing surgery for de novo renal cell carcinoma in allograft kidneys.

机译:保留异体移植肾脏新生肾细胞癌的保肾术。

获取原文
获取原文并翻译 | 示例

摘要

Renal cell carcinomas account for 4.6% of post-transplant cancers, 10% of which occur in allograft kidneys. We report three such cases among kidney grafts that were performed or followed from 1970 to 2004. In all patients, we performed a partial allograft nephrectomy after consideration of the tumor size, location, and absence of metastases and local extension. Renal function has remained stable, and there has been no sign of graft rejection, tumor recurrence or metastases. The surgery was technically feasible without exposing the patients to increased postoperative risks. The lateral, peripherally located tumor allowed excision without renal hilar dissection or entry into the collecting system. In agreement with data emerging from the literature, the present cases confirm that even in the setting of long-standing immunosuppression, de novo RCC of the kidney graft warrants a minimally invasive approach to spare patients graft loss and return to hemodialysis.
机译:肾细胞癌占移植后癌症的4.6%,其中10%发生在同种异体肾中。我们报告了从1970年至2004年进行或随访的肾移植物中的3例病例。在所有患者中,考虑到肿瘤的大小,位置以及是否存在转移和局部扩展,我们进行了部分同种异体肾切除术。肾功能保持稳定,没有移植排斥,肿瘤复发或转移的迹象。该手术在技术上是可行的,并且不会使患者面临更高的术后风险。肿瘤位于外侧,位于外围,无需切除肾门,也不会进入收集系统。与从文献中获得的数据一致,本病例证实,即使在长期免疫抑制的情况下,肾脏移植物的从头RCC仍需要微创方法以使患者移植物丢失并返回血液透析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号